Evidence map›Paper›PMID 34494500›Full record

ReviewInternational reviews of immunology2022

Antibody Response against SARS-CoV-2 Infection: Implications for Diagnosis, Treatment and Vaccine Development.

Alessandra Mallano, Alessandro Ascione, Michela Flego

Open access · bronzeAbstract readReview
In one paragraph

Review in International reviews of immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Rapid detection of SARS-CoV-2: The gradual boom of lateral flow immunoassay.Frontiers in bioengineering and biotechnology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Alessandra MallanoNational Center for Global Health, Istituto Superiore di Sanità (ISS), Rome, Italy.ORCID 0000-0003-2392-0769
Alessandro AscioneNational Center for Control and Evaluation of Medicine, Istituto Superiore di Sanità, Rome, Italy.ORCID 0000-0002-7208-4122
Michela FlegoNational Center for Global Health, Istituto Superiore di Sanità (ISS), Rome, Italy.ORCID 0000-0002-7720-7873
Istituto Superiore di Sanità · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Many recent studies have reported the onset of a robust antibody response to SARS-CoV-2 infection and highlighted produced antibodies' specific qualitative and quantitative aspects, relevant for developing antibody-based diagnostic and therapeutic options. In this review, firstly we will report main information acquired so far regarding the humoral response to COVID-19; we will concentrate, in particular, upon the observed levels and the kinetics, the specificity spectrum and the neutralizing potential of antibodies produced in infected patients. We will then discuss the implication of humoral response's characteristics in the development and correct use of serologic tests, as well as the efficacy and safety of convalescent plasma therapy and of neutralizing monoclonal antibodies for treating infected patients and preventing new infections. An update of the list of newly isolated specific neutralizing antibodies and suggestions for vaccine evaluation and development will be also provided.

Indexed as

COVID-19Antibodies, NeutralizingAntibodies, ViralAntibody FormationCOVID-19 SerotherapyHumansImmunization, PassiveSARS-CoV-2Spike Glycoprotein, CoronavirusVaccine DevelopmentAntibodies, NeutralizingAntibodies, ViralSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Convalescent plasmahumoral response to COVID-19neutralizing monoclonal antibodiesSARS-CoV-2serologic testsvaccine design

Identifiers

PMID34494500
PMCPMC8442988
OpenAlexW3197862932

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.